HSV vector-mediated modification of primary nociceptor afferents: An approach to inhibit chronic pain

Gene Therapy

Volumn 16, Issue 4, 2009, Pages 493-501

  Goss, J R ^a   Gold, M S ^a   Glorioso, J C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOMORPHIN 2; GLUTAMATE DECARBOXYLASE; HERPESVIRUS VECTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; PROTEIN KINASE C EPSILON; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; VANILLOID RECEPTOR 1; ZINC FINGER PROTEIN;

ANALGESIA; ANTINOCICEPTION; CHRONIC PAIN; DOWNSTREAM PROCESSING; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EXPRESSION VECTOR; GENE EXPRESSION; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS; HUMAN; MUSCLE SPINDLE AFFERENT NERVE; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SENSORY NERVE CONDUCTION; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM; VIRUS REACTIVATION;

CHRONIC DISEASE; GENE THERAPY; GENETIC VECTORS; HUMANS; NOCICEPTORS; PAIN; SIMPLEXVIRUS;

SIMPLEXVIRUS;

EID: 64549085942     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2009.24     Document Type: Review

References (55)

1. Niv D, Devor M. Chronic pain as a disease in its own right. Pain Pract 2004; 4: 179-181.
2. Dworkin RH, Gnann Jr JW, Oaklander AL, Raja SN, Schmader KE, Whitley RJ. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain 2008; 9: S37-S44.
3. Gold MS, Caterina MJ. Molecular biology of nociceptor transduction. In: Basbaum AI, Bushnell MC (eds). Handbook of the Senses, vol. 5. Academic Press: San Diego, 2008, pp 43-74.
4. Hansson P, Lacerenza M, Marchettini P. Aspects of clinical and experimental neuropathic pain: The clinical perspective. In: Hansson P, Fields HL, Hill RG, Marchettini P (eds). Neuropathic Pain: Pathophysiology and Treatment, vol. 21. IASP Press: Seattle, 2001, pp 1-18.
5. Barrett AM, Lucero MA, Le T, Robinson RL, Dworkin RH, Chappell AS. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: A review. Pain Med 2007; 8(Suppl 2): S50-S62.
6. Turk DC. Clinical effectiveness and cost-effectiveness of treatments for patients with chronic pain. Clin J Pain 2002; 18: 355-365.
7. Caterina MJ, Gold MS, Meyer RA. Molecular biology of nociceptors. In: Hunt S, Koltzenburg M, Hunt SP, Rothwell NJ (eds). The Neurobiology of Pain. Oxford University Press: Oxford, 2005, pp 1-33.
8. Braz J, Beaufour C, Coutaux A, Epstein AL, Cesselin F, Hamon M et al Therapeutic efficacy in experimental polyarthritis of viral-driven enkephalin overproduction in sensory neurons. J Neurosci 2001; 21: 7881-7888.
9. Schmelz M, Schmid R, Handwerker HO, Torebjork HE. Encoding of burning pain from capsaicin-treated human skin in two categories of unmyelinated nerve fibres. Brain 2000; 123 (Part 3): 560-571.
10. Xing H, Chen M, Ling J, Tan W, Gu JG. TRPM8 mechanism of cold allodynia after chronic nerve injury. J Neurosci 2007; 27: 13680-13690.
11. Gold MS, Chessell I, Devor M, Dray A, Gereau RW, Kane S et al. Peripheral nervous system targets: Rapporteur report. In: Campbell JN, Basbaum AI, Dray A, Dubner R, Dworkin RH, Sang CN (eds). Emerging Strategies for the Treatment of Neuropathic Pain. IASP Press: Seattle, 2006, pp 3-36.
12. Dubner R. The neurobiology of persistent pain and its clinical implications. Suppl Clin Neurophysiol 2004; 57: 3-7.
13. Gracely RH, Lynch SA, Bennett GJ. Painful neuropathy: Altered central processing maintained dynamically by peripheral input. Pain 1992; 51: 175-194.
14. Hill JM, Ball MJ, Neumann DM, Azcuy AM, Bhattacharjee PS, Bouhanik S et al. The high prevalence of herpes simplex virus type 1 DNA in human trigeminal ganglia is not a function of age or gender. J Virol 2008; 82: 8230-8234.
15. Jacobs A, Breakefield XO, Fraefel C. HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: Part I. HSV-1 structure, replication and pathogenesis. Neoplasia 1999; 1: 387-401.
16. Goins WF, Wolfe D, Krisky DM, Bai Q, Burton EA, Fink DJ et al. Delivery using herpes simplex virus: An overview. Methods Mol Biol 2004; 246: 257-299.
17. Chattopadhyay M, Goss J, Wolfe D, Goins WC, Huang S, Glorioso JC et al. Protective effect of herpes simplex virus-mediated neurotrophin gene transfer in cisplatin neuropathy. Brain 2004; 127: 929-939.
18. Burton EA, Wechuck JB, Wendell SK, Goins WF, Fink DJ, Glorioso JC. Multiple applications for replication-defective herpes simplex virus vectors. Stem Cells 2001; 19: 358-377.
19. DeLuca NA, McCarthy AM, Schaffer PA. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol 1985; 56: 558-570.
20. Krisky DM, Wolfe D, Goins WF, Marconi PC, Ramakrishnan R, Mata M et al. Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Therapy 1998; 5: 1593-1603.
21. Wolfe D, Goins WF, Yamada M, Moriuchi S, Krisky DM, Oligino TJ et al Engineering herpes simplex virus vectors for CNS applications. Exp Neurol 1999; 159: 34-46.
22. Craft AM, Krisky DM, Wechuck JB, Lobenhofer EK, Jiang Y, Wolfe DP et al. HSV-mediated expression of Pax3 and MyoD in embryoid bodies results in lineage-related alterations in gene expression profiles. Stem Cells 2008; 26: 3119-3129.
23. Kaplan KM, Brose WG. Intrathecal methods. Neurosurg Clin N Am 2004; 15: 289-296.
24. Antunes Bras JM, Epstein AL, Bourgoin S, Hamon M, Cesselin F, Pohl M. Herpes simplex virus 1-mediated transfer of preproenkephalin A in rat dorsal root ganglia. J Neurochem 1998; 70: 1299-1303.
25. Wilson SP, Yeomans DC, Bender MA, Lu Y, Goins WF, Glorioso JC. Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus. Proc Natl Acad Sci USA 1999; 96: 3211-3216.
26. Goss JR, Mata M, Goins WF, Wu HH, Glorioso JC, Fink DJ. Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. Gene Therapy 2001; 8 551-556.
27. Hao S, Mata M, Goins W, Glorioso JC, Fink DJ. Transgenemediated enkephalin release enhances the effect of morphine and evades tolerance to produce a sustained antiallodynic effect in neuropathic pain. Pain 2003; 102: 135-142.
28. Chuang YC, Yang LC, Chiang PH, Kang HY, Ma WL, Wu PC et al. Gene gun particle encoding preproenkephalin cDNA produces analgesia against capsaicin-induced bladder pain in rats. Urology 2005; 65: 804-810.
29. Lu Y, McNearney TA, Lin W, Wilson SP, Yeomans DC, Westlund KN. Treatment of inflamed pancreas with enkephalin encoding HSV-1 recombinant vector reduces inflammatory damage and behavioral sequelae. Mol Ther 2007; 15: 1812-1819.
30. Yeomans DC, Lu Y, Laurito CE, Peters MC, Vota-Vellis G, Wilson SP et al. Recombinant herpes vector-mediated analgesia in a primate model of hyperalgesia. Mol Ther 2006; 13: 589-597.
31. Wolfe D, Hao S, Hu J, Srinivasan R, Goss J, Mata M et al. Engineering an endomorphin-2 gene for use in neuropathic pain therapy. Pain 2007; 133: 29-38.
32. Hao S, Mata M, Wolfe D, Huang S, Glorioso JC, Fink DJ. Gene transfer of glutamic acid decarboxylase reduces neuropathic pain. Ann Neurol 2005; 57: 914-918.
33. Liu J, Wolfe D, Hao S, Huang S, Glorioso JC, Mata M et al. Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain. Mol Ther 2004; 10: 57-66.
34. Poole S, Cunha FQ, Selkirk S, Lorenzetti BB, Ferreira SH. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-10. Br J Pharmacol 1995; 115: 684-688.
35. Cunha FQ, Poole S, Lorenzetti BB, Veiga FH, Ferreira SH. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-4. Br J Pharmacol 1999; 126: 45-50.
36. Lorenzetti BB, Poole S, Veiga FH, Cunha FQ, Ferreira SH. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-13. Eur Cytokine Netw 2001; 12: 260-267.
37. Hao S, Mata M, Glorioso JC, Fink DJ. Gene transfer to interfere with TNFalpha signaling in neuropathic pain. Gene Therapy 2007; 14 1010-1016.
38. Goss JR, Fetterfolf C, Goins W, Wolfe D, Huang S, Krisky D et al. Additive effects of HSV vectors expressing proenkephalin, interleukin-4, and tumor necrosis factor alpha soluble receptor to treat bone cancer pain. Mol Pain 2004; 9(S1): 214.
39. Amir R, Argoff CE, Bennett GJ, Cummins TR, Durieux ME, Gerner P et al The role of sodium channels in chronic inflammatory and neuropathic pain. J Pain 2006; 7: S1-S29.
40. Waxman SG. Channel, neuronal and clinical function in sodium channelopathies: From genotype to phenotype. Nat Neurosci 2007; 10: 405-409.
41. Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature 2006; 444: 894-898.
42. Yeomans DC, Levinson SR, Peters MC, Koszowski AG, Tzabazis AZ, Gilly WF et al. Decrease in inflammatory hyperalgesia by herpes vector-mediated knockdown of Nav1.7 sodium channels in primary afferents. Hum Gene Ther 2005; 16: 271-277.
43. Goss JR, Zhang S, Qiao J, Galilei J, Krisky DM, Huang S et al. Engineered Zinc Finger Protein Transcription Factors as a Potential Therapy for Neuropathic Pain. 12th World Congress on Pain, Glasgow, Scotland, 2008.
44. Venkatachalam K, Montell C. TRP channels. Annu Rev Biochem 2007; 76: 387-417.
45. Honore P, Wismer CT, Mikusa J, Zhu CZ, Zhong C, Gauvin DM et al. A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. J Pharmacol Exp Ther 2005; 314: 410-421.
46. Wong GY, Gavva NR. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks. Brain Res Rev 2008; e-pub ahead of print 25 December 2008.
47. Hucho T, Levine JD. Signaling pathways in sensitization: Toward a nociceptor cell biology. Neuron 2007; 55: 365-376.
48. Numazaki M, Tominaga T, Toyooka H, Tominaga M. Direct phosphorylation of capsaicin receptor VR1 by protein kinase Cepsilon and identification of two target serine residues. J Biol Chem 2002; 277: 13375-13378.
49. Bhave G, Hu HJ, Glauner KS, Zhu W, Wang H, Brasier DJ et al. Protein kinase C phosphorylation sensitizes but does not activate the capsaicin receptor transient receptor potential vanilloid 1 (TRPV1). Proc Natl Acad Sci USA 2003; 100: 12480-12485.
50. Mandadi S, Tominaga T, Numazaki M, Murayama N, Saito N, Armati PJ et al. Increased sensitivity of desensitized TRPV1 by PMA occurs through PKCepsilon-mediated phosphorylation at S800. Pain 2006; 123: 106-116.
51. Sculptoreanu A, de Groat WC, Buffington CA, Birder LA. Protein kinase C contributes to abnormal capsaicin responses in DRG neurons from cats with feline interstitial cystitis. Neurosci Lett 2005; 381: 42-46.
52. Srinivasan R, Wolfe D, Goss J, Watkins S, de Groat WC, Sculptoreanu A et al. Protein kinase C epsilon contributes to basal and sensitizing responses of TRPV1 to capsaicin in rat dorsal root ganglion neurons. Eur J Neurosci 2008; 28: 1241-1254.
53. Srinivasan R, Huang S, Chaudhry S, Sculptoreanu A, Krisky D, Cascio M et al. An HSV vector system for selection of ligand-gated ion channel modulators. Nat Methods 2007; 4: 733-739.
54. Grandi P, Wang S, Schuback D, Krasnykh V, Spear M, Curiel DT et al HSV-1 virions engineered for specific binding to cell surface receptors. Mol Ther 2004; 9: 419-427.
55. Zhou G, Roizman B. Characterization of a recombinant herpes simplex virus 1 designed to enter cells via the IL13Ralpha2 receptor of malignant glioma cells. J Virol 2005; 79: 5272-5277.